Evidence map›Paper›PMID 42554051›Full record

ReviewDisease models & mechanisms2026

Cystic fibrosis: insights from zebrafish models.

Sarahdja Cornélie, Laure Yatime, Georges Lutfalla, Stephen A Renshaw, Audrey Bernut

Abstract readReview
In one paragraph

Review in Disease models & mechanisms, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sarahdja CornélieLaboratory of Pathogens and Host Immunity, CNRS, Inserm, Université de Montpellier, 34095 Montpellier, France.
Laure YatimeLaboratory of Pathogens and Host Immunity, CNRS, Inserm, Université de Montpellier, 34095 Montpellier, France.
Georges LutfallaLaboratory of Pathogens and Host Immunity, CNRS, Inserm, Université de Montpellier, 34095 Montpellier, France.
Stephen A RenshawThe Bateson Centre, School of Medicine and Population Health, University of Sheffield, Sheffield S10 2TN, UK.ORCID 0000-0003-1790-1641
Audrey BernutLaboratory of Pathogens and Host Immunity, CNRS, Inserm, Université de Montpellier, 34095 Montpellier, France.ORCID 0000-0002-1928-8329

Funding

Association Vaincre la Mucoviscidose RF20240503516/1/1/101Cystic Fibrosis Trust SRC018-G107734
6 · The paper itself

Abstract

Cystic fibrosis (CF) is a severe, life-limiting genetic disorder caused by mutations in the CFTR gene, which lead to defective epithelial ion transport, abnormally thick mucus and multi organ dysfunction, predominantly affecting the lungs, pancreas and digestive system. Despite significant advances in patient care, the complex interplay between CFTR dysfunction, chronic infection and persistent inflammation remains a major therapeutic challenge. In this context, animal models are indispensable for elucidating the cellular and molecular mechanisms underlying CF pathogenesis and accelerating drug discovery. Here, we review the relevance of the zebrafish (Danio rerio) as a powerful and complementary preclinical model for CF research. In particular, we highlight the unique advantages of zebrafish, including its highly conserved innate immune system and optical transparency, which together enable in vivo visualization of host immune responses under CF-like conditions at subcellular resolution. We further summarize how Cftr-deficient zebrafish models have provided key insights into the increased susceptibility to CF-relevant pathogens, disease mechanisms affecting the pancreas and the reproductive system, and the deleterious neutrophil-driven inflammation that characterizes CF. Finally, we discuss the potential of the zebrafish model for the identification and validation of novel therapeutic strategies to treat infectious and inflammatory lung pathology in CF, and outline future directions to expand its translational impact in CF research.

Indexed as

Cystic FibrosisZebrafishAnimalsCystic Fibrosis Transmembrane Conductance RegulatorDisease Models, AnimalHumansImmunity, InnateInflammationCystic Fibrosis Transmembrane Conductance RegulatorCFTRCystic fibrosisDrug discoveryInfectionsInflammationInnate immunityZebrafish

Identifiers

PMID42554051
PMCPMC13488410

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.